HONG KONG – An American pharmaceutical firm is working with a Japanese biotech company to combine two antibodies into a more effective immunotherapy for solid tumors. Read More
HONG KONG – A German-Japanese effort to develop a first-line therapy for advanced Asian hepatocellular carcinoma (HCC) recently hit an important milestone with the completion of a phase I trial and the launch of phase II development. Read More
BEIJING – The hot topic at this year's China Bio International 2014 was what type of strategy drugmakers should take to get innovative drugs on the market with China's challenging biologics manufacturing rules. It's clearly a high-stakes gamble, with innovators betting on one of three different horses to get them to the finish line. Read More
In a deal valued at up to $410 million, Tokyo's Daiichi Sankyo Co. Ltd. offered to buy San Diego-based Ambit Biosciences Inc., along with its pivotal-stage cancer drug quizartinib. Read More
HONG KONG – Following an approval in India, a U.S. biosimilars maker has partnered with its investor in China to expand its presence in emerging markets. Read More
HONG KONG - For the first time, Chinese scientists have identified the molecular mechanism underlying the anorexogenic effects of a safe and effective herbal dietary supplement that is widely used for weight control, providing a promising target for the development of novel obesity drugs. Read More
Breaking news often is the start of something bigger for drug developers and companies in the surrounding orbit. Starting with today's edition, BioWorld will include direct links to Thomson Reuters Cortellis for companies and drugs mentioned in lead articles. Read More
Tianyin Pharmaceutical Co. Inc., of Chengdu, China, said its Qionglai facility successfully completed the official site visit by the CFDA for its good manufacturing practice certification. Read More
